Drug combo breaks down cancer resistance to immunotherapy

Nonetheless, many patients either don't respond to immunotherapy, or if they do, the effects are temporary, which highlights how crucial it is that we better understand the mechanisms leading to cancers resisting this kind of treatment.

In a new study, scientists have found a way to break down the resistance of mice with neuroendocrine pancreatic cancer. This cancer is very resistant to a type of immunotherapy called, where the patient receives a drug that blocks proteins that normally keep immune responses from being too strong, but can also prevent immune cells from killing cancer cells.

The study was led by the group of Douglas Hanahan at EPFL's Swiss Institute for Experimental Cancer Research, with the Ludwig Institute for Cancer Research, the Lausanne University Hospital , the Swiss Institute for Bioinformatics, and Roche. The scientists evaluated a type of engineered protein-antibody fusion called an immunocytokine, which is increasingly used in immunotherapy. They focused on the bispecific immunocytokine PD1-IL2v, which is newly developed by Roche and can home in on tumors, wherein it activates killer T cells to attack the

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Rise of the natural red pigment ‘prodigiosin’ as an immunomodulator in cancer - Cancer Cell InternationalCancer is a heterogeneous disease with multifaceted drug resistance mechanisms (e.g., tumour microenvironment [TME], tumour heterogeneity, and immune evasion). Natural products are interesting repository of bioactive molecules, especially those with anticancer activities. Prodigiosin, a red pigment produced by Serratia marcescens, possesses inherent anticancer characteristics, showing interesting antitumour activities in different cancers (e.g., breast, gastric) with low or without harmful effects on normal cells. The present review discusses the potential role of prodigiosin in modulating and reprogramming the metabolism of the various immune cells in the TME, such as T and B lymphocytes, tumour-associated macrophages (TAMs), natural killer (NK) cells, and tumour-associated dendritic cells (TADCs), and myeloid-derived suppressor cells (MDSCs) which in turn might introduce as an immunomodulator in cancer therapy.
Source: BioMedCentral - 🏆 22. / 71 Read more »